RecruitingNCT06088134

Contrast-enhanced CT-based Deep Learning Model for Preoperative Prediction of Disease-free Survival (DFS) in Localized Clear Cell Renal Cell Carcinoma (ccRCC)

Urology Department of the First Affiliated Hospital of Chongqing Medical University


Sponsor

Mingzhao Xiao

Enrollment

800 participants

Start Date

Sep 1, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

This study aims to preoperatively predict DFS of patients with localised ccRCC using a deep learning prognostic model based on enhanced contrast CT images, validate it's predictive ability in multicentre data and compare it's predictive ability with traditional models.


Eligibility

Plain Language Summary

Simplified for easier understanding

This study is building and testing a computer (deep learning) model that uses CT scan images taken before surgery to predict how long a patient with clear cell kidney cancer (ccRCC) will remain disease-free after their tumor is removed. The goal is to help doctors better identify who might be at risk for cancer returning. **You may be eligible if...** - You had surgery (partial or complete kidney removal) for kidney cancer - Your cancer was confirmed as clear cell renal cell carcinoma (ccRCC) by pathology - You have complete medical records and pre-surgery CT scan images available **You may NOT be eligible if...** - Your medical or scan records are incomplete - You had chemotherapy or targeted therapy before or after surgery - You had multiple kidney tumors at the same time or cancer that had already spread - Your CT image quality is too poor for analysis Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Yingjie Xv

Chongqing, Chongqing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06088134


Related Trials